PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 16 2024
0mins
Should l Buy ?
Source: newsfilter
- Emergent Drug Shortages: Shortage of drug for African sleeping sickness prompts urgent need for access to the global drug market by affected nations.
- PaxMedica's Response: PaxMedica receives an urgent request from Malawi's Ministry of Health for emergency access to IV suramin to prevent a potential humanitarian crisis.
- FDA Involvement: PaxMedica brings the emergency request to the FDA to assess its impact on ongoing development programs and NDA submission plans for PAX-101.
- Clinical Studies: PaxMedica conducted clinical studies on TBR HAT patients treated with suramin, with many cases from Malawi, emphasizing the need for the drug in the region.
- PaxMedica's Initiatives: PaxMedica is working to respond to Malawi's request, collaborate with regulatory authorities, and potentially qualify for a Priority Review Voucher under the Neglected Tropical Disease Priority Review Voucher Program.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
